HOB BIOTECH(SH:688656) Xin Lang Cai Jing·2025-09-22 02:49Group 1 - The core point of the news is that Jiangsu Haobo Bio-Pharmaceutical Co., Ltd. experienced a stock decline of 5.11%, with the current share price at 155.50 yuan and a total market capitalization of 9.871 billion yuan [1] - The company was established on June 8, 2009, and went public on January 13, 2021, focusing on the research, production, and sales of in vitro diagnostic reagents [1] - The revenue composition of the company includes 89.46% from reagent sales, 5.86% from other sales, 3.84% from instrument sales, and 0.85% from rental sales [1] Group 2 - From the perspective of fund holdings, one fund under Nuoan Fund has a significant position in Haobo, with Nuoan Jingxin Mixed Fund holding 17,100 shares, accounting for 5.9% of the fund's net value, making it the third-largest holding [2] - The Nuoan Jingxin Mixed Fund was established on December 8, 2015, with a latest scale of 39.4081 million yuan, achieving a year-to-date return of 50.59% and a one-year return of 81.28% [2] - The fund manager, Li Yuliang, has a tenure of 10 years and 203 days, with the best fund return during his tenure being 197.09% and the worst being -86.55% [2]